BridgeMD
A Study Evaluating Bemarituzumab in Solid Tumors with FGFR2b Overexpression
EU CTIS ID: 2023-505455-44-00
What this study is testing
Phase 1b: To observe the safety and tolerability of bemarituzumab Phase 2: To evaluate preliminary antitumor activity
- Phase I and Phase II (Integrated)- Other
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Histologically or cytologically confirmed cancer of one of the following types, refractory to or relapsed after at least 1 prior standard therapeutic regimen in the advanced/metastatic setting, as specified below. If no standard of care therapies exists for the subject, or the subject cannot tolerate or refuses standard of care anticancer therapy, the subject may be allowed to participate on the study after discussion between the investigator and Amgen medical monitor. Subjects who have not received all approved or standard treatments for their cancer must be informed that these alternatives to receiving bemarituzumab are available prior to consenting to participate in the trial. head and neck squamous cell carcinoma: ≥ 1 line of therapy triple-negative breast cancer: ≥ 2 lines of therapy intrahepatic cholangiocarcinoma: ≥ 1 line of therapy Lung adenocarcinoma: at least platinum-based chemotherapy, checkpoint inhibitor, and targeted therapy (ie, if molecular testing has identified targetable mutations in EGFR, ALK, etc) platinum-resistant ovarian epithelial carcinoma, including fallopian tube cancers and primary peritoneal cancers, defined as progression during or within 6 months of a platinum containing regimen: ≥ 1 line of therapy endometrial adenocarcinoma: ≥ 1 line of therapy cervical carcinoma: ≥ 1 line of therapy other solid tumors: ≥ 1 line of therapy
- Tumor overexpresses FGFR2b as determined by centrally performed IHC testing
- Measurable disease per RECIST v1.1
- Adequate hematologic and organ function, defined as follows: Absolute neutrophil count ≥ 1.5 x 109/L Platelet count ≥ 100 x 109/L Hemoglobin ≥ 9 g/dL AST and ALT < 3 x upper limit of Normal [ULN] (or < 5 x ULN in case of liver involvement). Total bilirubin < 1.5 x ULN (or < 2 x ULN in case of liver involvement or Gilbert’s disease) Calculated or measured creatinine clearance (CrCl) of ≥ 30 mL/minute calculated using the formula of Cockcroft and Gault ([140 – Age] x Mass[kg]/[72 x Creatinine mg/dL) (x 0.85 if female). International normalized ratio (INR) or prothrombin time (PT) < 1.5 × ULN except for subjects receiving anticoagulation therapy, who must be on stable dose of anticoagulant therapy for 6 weeks prior to enrollment.
You likely can't join if
- Untreated or symptomatic central nervous system (CNS) metastases or leptomeningeal disease Subjects with asymptomatic CNS metastases are eligible if clinically stable for at least 4 weeks and do not require intervention (including use of corticosteroids). Subjects with treated brain metastases are eligible provided the following criteria are met: Definitive therapy was completed at least 2 weeks prior to the first planned dose of study treatment (stereotactic radiosurgery at least 7 days prior to first planned dose of study treatment). At least 7 days prior to first planned dose of study treatment: any CNS disease is clinically stable, subject is off steroids for CNS disease (unless steroids are indicated for a reason unrelated to CNS disease), and subject is off or on stable doses of anti-epileptic drugs.
- Major surgical procedure within 28 days prior to first dose of study treatment
- Female subjects of childbearing potential unwilling to use protocol specified method of contraception during treatment and for an additional 90 days after the last dose of bemarituzumab.
- Other solid tumor cohort excludes primary tumors of the CNS, squamous non-small cell lung cancer, gastric adenocarcinoma, and gastroesophageal junction adenocarcinoma
- History of other malignancy within the past 2 years, with the following exceptions: curatively treated non-melanoma skin malignancy cervical cancer in situ curatively treated uterine cancer stage I curatively treated ductal or lobular breast carcinoma in situ and not currently receiving any systemic therapy localized prostate cancer that has been treated surgically with curative intent and presumed cured
- Impaired cardiac function or clinically significant cardiac disease including: unstable angina within 6 months prior to first dose of study treatment, acute myocardial infarction < 6 months prior to first dose of study treatment, New York Heart Association (NYHA) class II-IV congestive heart failure, uncontrolled hypertension (defined as an average systolic blood pressure > 160 mmHg or diastolic >100 mmHg despite optimal treatment, uncontrolled cardiac arrhythmias requiring anti-arrhythmic therapy other than beta blockers or digoxin, active coronary artery disease or corrected QT interval (QTc) ≥ 470.
See the full eligibility criteria
Who can join
- Histologically or cytologically confirmed cancer of one of the following types, refractory to or relapsed after at least 1 prior standard therapeutic regimen in the advanced/metastatic setting, as specified below. If no standard of care therapies exists for the subject, or the subject cannot tolerate or refuses standard of care anticancer therapy, the subject may be allowed to participate on the study after discussion between the investigator and Amgen medical monitor. Subjects who have not received all approved or standard treatments for their cancer must be informed that these alternatives to receiving bemarituzumab are available prior to consenting to participate in the trial. head and neck squamous cell carcinoma: ≥ 1 line of therapy triple-negative breast cancer: ≥ 2 lines of therapy intrahepatic cholangiocarcinoma: ≥ 1 line of therapy Lung adenocarcinoma: at least platinum-based chemotherapy, checkpoint inhibitor, and targeted therapy (ie, if molecular testing has identified targetable mutations in EGFR, ALK, etc) platinum-resistant ovarian epithelial carcinoma, including fallopian tube cancers and primary peritoneal cancers, defined as progression during or within 6 months of a platinum containing regimen: ≥ 1 line of therapy endometrial adenocarcinoma: ≥ 1 line of therapy cervical carcinoma: ≥ 1 line of therapy other solid tumors: ≥ 1 line of therapy
- Tumor overexpresses FGFR2b as determined by centrally performed IHC testing
- Measurable disease per RECIST v1.1
- Adequate hematologic and organ function, defined as follows: Absolute neutrophil count ≥ 1.5 x 109/L Platelet count ≥ 100 x 109/L Hemoglobin ≥ 9 g/dL AST and ALT < 3 x upper limit of Normal [ULN] (or < 5 x ULN in case of liver involvement). Total bilirubin < 1.5 x ULN (or < 2 x ULN in case of liver involvement or Gilbert’s disease) Calculated or measured creatinine clearance (CrCl) of ≥ 30 mL/minute calculated using the formula of Cockcroft and Gault ([140 – Age] x Mass[kg]/[72 x Creatinine mg/dL) (x 0.85 if female). International normalized ratio (INR) or prothrombin time (PT) < 1.5 × ULN except for subjects receiving anticoagulation therapy, who must be on stable dose of anticoagulant therapy for 6 weeks prior to enrollment.
What rules you out
- Untreated or symptomatic central nervous system (CNS) metastases or leptomeningeal disease Subjects with asymptomatic CNS metastases are eligible if clinically stable for at least 4 weeks and do not require intervention (including use of corticosteroids). Subjects with treated brain metastases are eligible provided the following criteria are met: Definitive therapy was completed at least 2 weeks prior to the first planned dose of study treatment (stereotactic radiosurgery at least 7 days prior to first planned dose of study treatment). At least 7 days prior to first planned dose of study treatment: any CNS disease is clinically stable, subject is off steroids for CNS disease (unless steroids are indicated for a reason unrelated to CNS disease), and subject is off or on stable doses of anti-epileptic drugs.
- Major surgical procedure within 28 days prior to first dose of study treatment
- Female subjects of childbearing potential unwilling to use protocol specified method of contraception during treatment and for an additional 90 days after the last dose of bemarituzumab.
- Other solid tumor cohort excludes primary tumors of the CNS, squamous non-small cell lung cancer, gastric adenocarcinoma, and gastroesophageal junction adenocarcinoma
- History of other malignancy within the past 2 years, with the following exceptions: curatively treated non-melanoma skin malignancy cervical cancer in situ curatively treated uterine cancer stage I curatively treated ductal or lobular breast carcinoma in situ and not currently receiving any systemic therapy localized prostate cancer that has been treated surgically with curative intent and presumed cured
- Impaired cardiac function or clinically significant cardiac disease including: unstable angina within 6 months prior to first dose of study treatment, acute myocardial infarction < 6 months prior to first dose of study treatment, New York Heart Association (NYHA) class II-IV congestive heart failure, uncontrolled hypertension (defined as an average systolic blood pressure > 160 mmHg or diastolic >100 mmHg despite optimal treatment, uncontrolled cardiac arrhythmias requiring anti-arrhythmic therapy other than beta blockers or digoxin, active coronary artery disease or corrected QT interval (QTc) ≥ 470.
- Active infection requiring systemic treatment or any uncontrolled infection within 14 days prior to first dose of study treatment
- Known human immunodeficiency virus (HIV) infection with CD4+ T-cell (CD4+) counts <350 cells/μL, hepatitis C infection (subjects with hepatitis C that achieve a sustained virologic response following antiviral therapy are allowed), or hepatitis B infection (subjects with hepatitis B surface antigen [SAg] or core antibody that achieve sustained virologic response with antiviral therapy directed at hepatitis B are allowed).
- History of systemic disease or ophthalmologic disorders requiring chronic use of ophthalmic steroids
- Prior treatment with any investigational selective inhibitor of the FGF-FGFR pathway (unless approved standard of care for tumor indication)
- Any anticancer therapy or immunotherapy within 4 weeks prior to enrollment; Palliative radiotherapy is allowed, provided it has been completed more than 14 days prior to the first dose of study treatment All treatment-related toxicity needs to be resolved to grade ≤ 1 prior to the first dose of study treatment, with exception of alopecia or toxicities considered irreversible (defined as having been present and stable > 21 days) which are not otherwise described in the exclusion criteria
The study team makes the final eligibility decision.
Where it's taking place
- United States
- Israel
- Korea, Republic of
- Mexico
- Turkey
- Canada
- Argentina
- Russian Federation
- Switzerland
- United Kingdom
- Japan
- Brazil
- Australia
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include United States; Israel; Korea, Republic of; Mexico; Turkey; Canada and 7 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.